Oct 16, 2026 02:50AM
Oct 8, 2026 08:01AM
Oct 8, 2026 08:00AM
Sep 22, 2026 07:01AM
Sep 22, 2026 07:00AM
Aug 6, 2026 08:00AM
Jul 13, 2026 08:30AM Edgewise sells muscular dystrophy drug to Servier for up to $2.65B
Jul 13, 2026 08:30AM
Jun 17, 2026 05:30AM
Jun 16, 2026 10:18AM
Jun 16, 2026 07:00AM
Jun 16, 2026 07:00AM
Jun 1, 2026 08:31AM
Jun 1, 2026 08:30AM Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
May 7, 2026 08:00AM
Mar 10, 2026 07:02AM
Mar 10, 2026 07:00AM
Mar 3, 2026 08:00AM
Feb 26, 2026 08:00AM
Jan 13, 2026 08:00AM
Dec 24, 2025 08:00AM Edgewise completes phase 2 trial parts, reports safety data for heart drug
Dec 24, 2025 08:00AM
Dec 22, 2025 07:06AM
Nov 20, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Nov 6, 2025 08:00AM Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Oct 2, 2025 08:00AM
Sep 11, 2025 08:18AM
Aug 8, 2025 08:43AM
Aug 7, 2025 10:44AM
Aug 7, 2025 08:00AM
Jul 3, 2025 10:00AM
Jul 1, 2025 10:00AM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
Jun 28, 2025 10:00AM
Jun 26, 2025 10:32AM
Jun 26, 2025 06:00AM
Jun 26, 2025 06:00AM
Jun 11, 2025 08:35AM
Jun 5, 2025 08:53AM
May 8, 2025 08:00AM Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Mar 11, 2025 08:00AM
Mar 10, 2025 09:44AM
Mar 3, 2025 08:00AM
Jan 13, 2025 12:50PM
Jan 13, 2025 08:00AM
Jan 2, 2025 12:51PM
Dec 16, 2024 06:05AM Edgewise Therapeutics Inc. (EWTX) Reports Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten
Dec 16, 2024 06:00AM

335,322 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All